Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Laura Ravanti
ODM-201, a New Generation Androgen Receptor Inhibitor for Castration-Resistant Prostate Cancer: Preclinical and Phase I Data.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Androgen Receptor Inhibitor–induced “BRCAness” and PARP Inhibition Are Synthetically Lethal for Castration-Resistant Prostate Cancer
Science Signaling
Biochemistry
Cell Biology
Molecular Biology
The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Hormones and Cancer
Oncology
Cancer Research
Endocrinology
Autonomic Systems
Endocrine
Metabolism
Diabetes
Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
BAY 1024767 Blocks Androgen Receptor Mutants Found in Castration-Resistant Prostate Cancer Patients
Oncotarget
Oncology
Increased Androgen Receptor Transcription: A Cause of Castration-Resistant Prostate Cancer and a Possible Therapeutic Target
Journal of Molecular Endocrinology
Endocrinology
Molecular Biology
Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer
Expert Review of Anticancer Therapy
Oncology
Pharmacology
Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate Cancer
Cancer Research
Cancer Research
Oncology
Phase III Data for Abiraterone in an Evolving Landscape for Castration-Resistant Prostate Cancer
Maturitas
Biochemistry
Gynecology
Genetics
Obstetrics
Molecular Biology
Ailanthone: A New Potential Drug for Castration-Resistant Prostate Cancer
Chinese Journal of Cancer
